



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgooffice@wjgnet.com <http://www.wjgnet.com>

Name of Journal: *World Journal of Gastrointestinal Oncology*

ESPS Manuscript NO: 21801

Manuscript Type: EVIDENCE-BASED MEDICINE

Cuneo, 8th October 2015

World Journal of Gastrointestinal Oncology

Lian-Sheng Ma, President and Company Editor-in-Chief

Baishideng Publishing Group Inc

Dear Editor,

Please, find enclosed the revised version of the manuscript entitled "**Evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)**" by Cristiana Lo Nigro et al.

We would like to re-submit this paper for publication on "*World Journal of Gastrointestinal Oncology*" as Original Article in the Column: "Evidence-Based Medicine".

We thank the Editor and Reviewer #1 for the comments; the manuscript changes are reported below.

Reviewer #1

The current study reported prognosis impact of CD1d-restricted natural killer T (iNKT) cells, antibody-dependent cell-mediated cytotoxicity (ADCC) and their correlation with EGFR level, mutational status of KRAS, NRAS, and BRAF in metastatic colorectal cancer (mCRC) patients. Though the sample size (n=41) is limited, which was also indicated by the author, this study provides some interesting information, particularly for cetuximab mediated ADCC. However, the manuscript has to be improved to be more informative to the audience.

Point (1): Please spell out iNKT, ADCC, NK, LDH etc. in the abstract.

We have spelt out the acronyms in the abstract section.

Point (2): In the abstract, please briefly state that the "standard techniques" are for the mutation analysis.

We give a short description for the "standard techniques" changing with the sentence "...was determined either by sequencing or allelic discrimination assays".

Point (3): *Figure 2 is currently missing.*

We apologize ourselves for the missing Figure 2 that now we have put in the correct position of the text.

Point (4): *The discussion section is too long to be balanced with the result section. You may consider deleting some clinical trial information and focusing the discussion on the result.*

We agree with the Referee #1 that this section was too long so that we have modified it according with his suggestions.

Point (5): *No multivariate statistical analysis was performed for disease free and overall survival analyses.*

In order to define the prognosticator marker in mCRC with the best relation to DFS and OS, we attempted to perform a multivariate analysis with the clinical parameters reported in Table 1. Unluckily, probably due to the low number of patients, we found only a parameter, among those studied, with a significant value in the univariate analysis, that is the ADCC activity at basal. This is why we were not able to correctly run the multivariate analysis and we decided not to mention it in the manuscript.

Editor

We've answered all the comments from the Editor and corrected the text consequently. We are sorry, but we were not able to provide an audio core tip due to technological limitation of our Institution.

We thank the Editor and Reviewer #1 for their useful suggestions and we resubmit the manuscript. We hope that it could be reevaluated for publication.

Thank you again for the attention you will dedicate to our work.
We will wait for an answer at your earliest convenience,

Best regards
Dr. Cristiana Lo Nigro
on the behalf of all the authors

Cristiana Lo Nigro

Laboratorio di Genetica Oncologica e di Oncologia Translazionale, SC Oncologia
ASO S. Croce e Carle, via Carle 25
12100 Cuneo
Phone: +39 0171 616338
Fax: +39 0171 616331
e-mail: lonigro.c@ospedale.cuneo.it